Merck’s strong oncology gains, 4% yield, and low PEG ratio support its value case despite sector risks and patent concerns.

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s earnings beat estimates, its sales came in line. Earnings of $2.13 per ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the ...

Is Merck's stock worth buying right now? Merck's stock has been mired in bad news, with concerns around Keytruda and Gardasil's underwhelming performance weighing on its valuation.

Merck (MRK) is set to present new clinical trial data at the European Society of Cardiology Congress 2025, emphasizing advancements in cardiovascular disease management. Over the last quarter, Merck's ...

Merck (MRK) is seeing renewed attention from investors this week, thanks to a pivotal event in its oncology pipeline. The company, in collaboration with Daiichi Sankyo, just secured Breakthrough ...

Merck & Co reports Q1 earnings on Thursday with EPS of $2.14 and revenue of $15.33B expected. Despite a 38.04% drop in stock over past year, analysts see ~30% upside potential.

Amgen and Merck: The P/E ratio The price-to-earnings (P/E) ratio is a financial metric that divides a stock's price by its earnings per share (EPS) as a quick way to assess a company's valuation.

Merck MRK operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The 52-week range of Merck stock price was $75.93 to $134.63. Merck's ...

Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.